This article examines how this technology produces new avenues for medical overuse among people who are unlikely to gain clinical benefit, and who as active consumers become medicalised via taking part in disease-specific monitoring.
The evidence for the effectiveness of PCC and SDM has been accepted and further research is now shifting towards implementation into practice and tailoring of resources to groups or contexts where needs are identified.
Non-invasive prenatal screening (NIPS) is being increasingly used by expectant parents. Much provision of this test in Australia is occurring in clinical settings where specialised genetic counselling is unavailable, such as general practice.
Pathology testing and diagnostic imaging together contribute 9% of healthcare's carbon footprint. Whilst the carbon footprint of pathology testing has been undertaken, to date, the carbon footprint of the four most common imaging modalities is unclear.
Systematic ethical evaluations of healthcare AI tools, using a framework such as we propose, should be included in published reports of new AI interventions. Such an approach has both a prospective benefit, shaping the way that AI tools are developed, and a retrospective benefit, allowing [...]
The aim of this systematic review and meta-analysis was to describe and quantify socioeconomic differences in use of prostate cancer treatment in the literature.
Using risk stratification to determine eligibility for cancer screening is likely to improve the efficiency of screening programmes by targeting resources towards those most likely to benefit. We aimed to explore the implications of this approach from a societal perspective by understanding public views on [...]
We encourage others to clarify such practice variations and begin the journey to safely reducing anesthesia’s environmental footprint.
The aim of this study was to determine whether using sensors to achieve soft-tissue balance was more effective than manual balancing in improving outcomes in TKA.
This study aimed to formally develop valid clinical quality indicators for the diagnosis and early management of cutaneous melanoma as an important step in creating the registry.